Credit: Getty Images. Starting treatment for advanced NSCLC before receiving genomic test results compromises patient outcomes, a study suggests. Starting treatment for advanced non-small cell lung ...
Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results